WESTPORT, CT (Reuters Health) – Postmenopausal women who have an acute myocardial infarction (AMI) are at increased risk for stroke, regardless of whether they use of hormone replacement therapy (HRT) or not, according to a report in the November 1st issue of the Journal of the American College of Cardiology.
Using the third National Registry of Myocardial Infarction, Dr. Brad G. Angeja from the University of California, San Francisco, and colleagues collected data on 114,724 women, 55 years of age or older, who were hospitalized for AMI. Among these women 7353 reported using HRT.
In the total population, there were 2152 in-hospital strokes: 442 hemorrhagic strokes and 1017 ischemic strokes and 693 unspecified.
Women on HRT and those not using HRT had similar risk of stroke. Rates for ischemic stroke were 0.80% for women on HRT versus 0.96% for HRT non-users, and rates for hemorrhagic stroke were 0.40% for HRT users versus 0.42% for non-users, Dr. Angeja's group found.
Hemorrhagic stroke rates were also similar for HRT users and non-users among the 13,328 women who received thrombolytic therapy (1.6% for users versus 2.1% for non-users). In-hospital mortality after stroke was also similar among women on HRT and nonusers (42% versus 40%, p = 0.61), the investigators note.
When Dr. Angeja's team adjusted for baseline and treatment differences among the women they found that hemorrhagic stroke was not associated with HRT (odds ratio 0.88) or with ischemic stroke (odds ratio 0.89).
Based on these findings "clinicians should not alter their approach to thrombolytic therapy in AMI based on HRT use," Dr. Angeja and colleagues advise.
J Am Coll Cardiol 2001;38:1297-1301.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!